Pharmacy utilization and the medicare modernization act

Milbank Quarterly

Volumn 83, Issue 1, 2005, Pages 101-130

  Maio, Vittorio ^a   Pizzi, Laura ^a   Roumm, Adam R ^a   Clarke, Janice ^a   Goldfarb, Neil I ^a   Nash, David B ^a   Chess, David ^a,b,c,d  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Project Patient Care

^d Project Patient Care ^*

Author keywords

Administrative restriction tools; Cost sharing mechanisms; Pharmacy utilization management; Seniors

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANALGESIC AGENT; ANTIANGINA PECTORIS AGENT; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTITUSSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BRONCHODILATING AGENT; CERIVASTATIN; CHOLINERGIC RECEPTOR STIMULATING AGENT; DIURETIC AGENT; GASTROINTESTINAL AGENT; HYPNOTIC AGENT; INSULIN; NITRIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; SEDATIVE AGENT; SIMVASTATIN; WARFARIN;

ARTICLE; COST CONTROL; DRUG COST; DRUG FORMULARY; DRUG UTILIZATION; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEALTH INSURANCE; HEALTH PROGRAM; HEALTH SERVICE; HUMAN; LITERATURE; MEDICAID; MEDICARE; NURSING HOME; PHARMACY UTILIZATION MANAGEMENT; PRESCRIPTION; SIDE EFFECT; AGED; DRUG USE; ECONOMICS; INSURANCE; LEGAL ASPECT; ORGANIZATION AND MANAGEMENT; POVERTY; REVIEW; STATISTICS; UNITED STATES; UTILIZATION REVIEW;

AGED; DRUG UTILIZATION REVIEW; HUMANS; INSURANCE BENEFITS; INSURANCE CLAIM REVIEW; INSURANCE COVERAGE; INSURANCE, PHARMACEUTICAL SERVICES; MEDICARE; POVERTY; PRESCRIPTIONS, DRUG; PRIVATIZATION; UNITED STATES;

EID: 16244422607     PISSN: 0887378X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0887-378X.2005.00337.x     Document Type: Article

References (70)

1. AARP. 1999. Administration on Aging. A Profile of Older Americans. Washington, D.C.
2. AARP. 2003. What Does the New Medicare Drug Benefit Mean for You? Available at http://www.aarp.org/bulletin/prescription/Articles/a2003-11-26- foryou.html (accessed December 10, 2003).
3. Andrade, S.E., and J.H. Gurwitz. 2002. Drug Benefit Plans under Managed Care: To What Extent Do Older Subscribers Selecting Less Drug Coverage Put Themselves at Increased Financial Risk? Journal of American Geriatrics Society 50:178-81.
4. Arnett, R.H. III, L.A. Blank, A.P. Brown, C.A. Cowan, C.S. Donham, M.S. Freeland, H.C. Lazenby, S.W. Letsch, K.R. Levit, B.T. Maple, P.A. McDonnell, S.T. Sonnefeld, M.W. Stewart, and D.R. Waldo. 1990. National Health Expenditures, 1988. Office of National Cost Estimates. Health Care Financing Review 11:1-41.
5. Beers, M.H., R.W. Baran, and K. Frenia. 2000. Drugs and the Elderly, Part 1: The Problems Facing Managed Care. American Journal of Managed Care 6:1313-20.
6. Biais, L., J.M. Boucher, J. Couture, E. Rahme, and J. LeLorier. 2001. Impact of a Cost-Sharing Drug Insurance Plan on Drug Utilization among Older People. Journal of American Geriatrics Society 49:410-4.
7. Bloor, K., and N. Freemantle. 1996. Lessons from International Experience in Controlling Pharmaceutical Expenditure. II: Influencing Doctors. BMJ 312:1525-7.
8. Bloor, K., A. Maynard, and N. Freemantle. 1996. Lessons from International Experience in Controlling Pharmaceutical Expenditure. III: Regulating Industry. BMJ 313:33-5.
9. Broyles, R. W., L. Narine, E.N. Brandt Jr., and D. Biard-Holmes. 2000. Health Risks, Ability to Pay, and the Use of Primary Care: Is the Distribution of Service Effective and Equitable? Preventive Medicine 30:453-62.
10. Commonwealth Fund. 2003. Despite Medicare Bill's Passage, Congress's Work Unfinished. Available at http://www.cmwf.org/programs/medfutur/ postmedicarevote_2ndpg.asp (accessed December 9, 2003).
11. Condra, L.J., A.P. Morreale, S.N. Stolley, and D. Marcus. 1999. Assessment of Patient Satisfaction with a Formulary Switch from Omeprazole to Lansoprazole in Gastroesophageal Reflux Disease Maintenance Therapy. American Journal of Managed Care 5:631-8.
12. Cox, E.R., C. Jernigan, S.J. Coons, and J.L. Draugalis. 2001. Medicare Beneficiaries' Management of Capped Prescription Benefits. Medical Care 39:296-301.
13. Cox, E.R., B.R. Motheral, and K. Fairman. 2000. Exhaustion of Prescription Benefits and Medicare Beneficiaries' Disenrollment from Managed Care. Journal of the American Medical Association 284:2596-7.
14. Cromwell, D.M., E.B. Bass, E.P. Steinberg, Y. Yasui, W.J. Ravich, T.R. Hendrix, S.F. McLeod, and R.D. Moore. 1999. Can Restrictions on Reimbursement for Anti-Ulcer Drugs Decrease Medicaid Pharmacy Costs without Increasing Hospitalizations? Health Services Research 33:1593-1610.
15. Curtiss, F.R. 1996. Drug Formularies Provide a Path to Best Care. American Journal Health System Pharmacy 53:2201-3.
16. Elwood, T.W. 2000. The Challenge of Expanding Health Benefits for the Aged. Journal of Allied Health 29:189-95.
17. Fortess, E.E., S.B. Soumerai, T.J. McLaughlin, and D. Ross-Degnan. 2001. Utilization of Essential Medications by Vulnerable Older People after a Drug Benefit Cap: Importance of Mental Disorders, Chronic Pain, and Practice Setting. Journal of American Geriatrics Society 49:793-7.
18. Freemantle, N., and K. Bloor. 1996. Lessons from International Experience in Controlling Pharmaceutical Expenditure. I: Influencing Patients. BMJ 312:1469-71.
19. Good, C.B., S.L. Fultz, L. Trilli, and J. Etchason. 2000. Therapeutic Substitution of Cimetidine for Nizatidine Was Not Associated with an Increase in Healthcare Utilization. American Journal of Managed Care 6:1141-6.
20. Gustin, G., W.B. White, S. Taylor, and C. Daragjati. 1996. Clinical Outcome of a Mandatory Formulary Switch for Dihydropyridine Calcium Channel Blocker Therapy at a Veterans Administration Medical Center. American Journal of Hypertension 9:312-6.
21. Henderson, J.D., and R.H. Esham. 2001. Generic Substitution: Issues for Problematic Drugs. Southern Medical Journal 94:16-21.
22. Horn, S.D., P.D. Sharkey, and J. Gassaway. 1996. Managed Care Outcomes Project: Study Design, Baseline Patient Characteristics, and Outcome Measures. American Journal of Managed Care 2:237-47.
23. Horn, S.D., P.D. Sharkey, and C. Phillips-Harris. 1998. Formulary Limitations and the Elderly: Results from the Managed Care Outcomes Project. American Journal of Managed Care 4:1105-13.
24. Huskamp, H.A., P.A. Deverka, A.M. Epstein, R.S. Epstein, K.A. McGuigan, and R.G. Frank. 2003. The Effect of Incentive-Based Formularies on Prescription-Drug Utilization and Spending. New England Journal of Medicine 349:2224-32.
25. Iglehart, J.K. 2001. Medicare and Prescription Drugs. New England Journal of Medicine 344:1010-5.
26. Johnson, R.E., M.J. Goodman, M.C. Hornbrook, and M.B. Eldredge. 1997a. The Effect of Increased Prescription Drug Cost-Sharing on Medical Care Utilization and Expenses of Elderly Health Maintenance Organization Members. Medical Care 35:1119-31.
27. Johnson, R.E., M.J. Goodman, M.C. Hornbrook, and M.B. Eldredge. 1997b. The Impact of Increasing Patient Prescription Drug Cost Sharing on Therapeutic Classes of Drugs Received and on the Health Status of Elderly HMO Members. Health Services Research 32:103-22.
28. Joyce, G.F., J.J. Escarce, M.D. Solomon, and D.P. Goldman. 2002. Employer Drug Benefit Plans and Spending on Prescription Drugs. Journal of the American Medical Association 288:1733-9.
29. Kaiser Commission on Medicaid and the Uninsured. 2003. Prior Authorization for Medicaid Prescription Drugs in Five States: Lessons for Policy Makers. Available at http://www.kff.org/medicaid/4094-index.cfm (accessed December 10, 2003).
30. Kaiser Family Foundation. 2003. Medicare and Prescription Drug Spending Chartpack. Available at http://www.kff.org/medicare/6087-index.cfm (accessed June 10, 2004).
31. Levy, R.A. 1992. Prescription Cost Sharing: Economic and Health Impacts, and Implications for Health Policy. Pharmacoeconomics 2:219-37.
32. Lexchin, J. 2002. Effects of Restrictive Formularies in the Ambulatory Care Setting. American Journal of Managed Care 8:69-76.
33. Lexchin, J., and P. Grootendorst. 2004. Effects of Prescription Drug User Fees on Drug and Health Services Use and on Health Status in Vulnerable Populations: A Systematic Review of the Evidence. International Journal of Health Services 34:101-22.
34. MacKinnon, N., and R. Kumar. 2001. Prior Authorization Programs: A Critical Review of the Literature. Journal of Managed Care Pharmacy 7:297-302.
35. Mercer Human Resources Consulting. 2003. Fifteenth Annual Mercer/Foster Higgins National Survey of Employer-Sponsored Health Plans. Available at http://imercer.com/us/imercercommentary/home.asp (accessed July 15, 2003).
36. Milligan, P.E., G.A. Banet, A.D. Waterman, S.K. Gatchel, and B.F. Gage. 2002. Substitution of Generic Warfarin for Coumadin in an HMO Setting. Annals of Pharmacotherapy 36:764-8.
37. Moon, M. 2004. How Beneficiaries Fare under the New Medicare Drug Bill. Issue Brief (Commonwealth Fund), no. 730, 1-16.
38. Motheral, B., and K.A. Fairman. 2001. Effect of a Three-Tier Prescription Copay on Pharmaceutical and Other Medical Utilization. Medical Care 39:1293-1304.
39. Murphy, J.E. 1999. Generic Substitution and Optimal Patient Care. Archives of Internal Medicine 159:429-33.
40. Nair, K., P. Wolfe, R.J. Valuck, M.M. McCollum, J.M. Ganther, and S.J. Lewis. 2003- Effects of a 3-Tier Pharmacy Benefit Design on the Prescription Purchasing Behavior of Individuals with Chronic Disease. Journal of Managed Care Pharmacy 9:123-33.
41. National Pharmaceutical Council. 2001. Pharmaceutical Benefits under State Medical Assistance Programs, 2001. Available at http://www.npcnow.org/ issues_productlist/medicaidpharmaceutical. asp (accessed July 15, 2003).
42. Nelson, A.A., Jr., C.E. Reeder, and W.M. Dickson. 1984. The Effect of a Medicaid Drug Copayment Program on the Utilization and Cost of Prescription Services. Medical Care 22:724-36.
43. Oliver, T.R., P.R. Lee, and H.L. Lipton. 2004. A Political History of Medicare and Prescription Drug Coverage. Milbank Quarterly 82:283-354.
44. Olson, B.M. 2003. Approaches to Pharmacy Benefit Management and the Impact of Consumer Cost Sharing. Clinical Therapeutics 25:250-72.
45. Penna, P. 2000. Three-Tier Copay Systems and Consumer-Centric Care. Journal of Managed Care Pharmacy 6:351-4.
46. Pilote, L., C. Beck, H. Richard, and M.J. Eisenberg. 2002. The Effects of Cost-Sharing on Essential Drug Prescriptions, Utilization of Medical Care and Outcomes after Acute Myocardial Infarction in Elderly Patients. Canadian Medical Association Journal 167:246-52.
47. Poisal, J.A., and L. Murray. 2001. Growing Differences between Medicare Beneficiaries with and without Drug Coverage. Health Affairs 20:74-85.
48. Rector, T.S. 2000. Exhaustion of Drug Benefits and Disenrollment of Medicare Beneficiaries from Managed Care Organizations. Journal of the American Medical Association 283:2163-7.
49. Rector, T.S., M.D. Finch, P.M. Danzon, M.V. Pauly, and B.S. Manda. 2003. Effect of Tiered Prescription Copayments on the Use of Preferred Brand Medications. Medical Care 41:398-406.
50. Reeder, C.E., and A.A. Nelson. 1985. The Differential Impact of Copayment on Drug Use in a Medicaid Population. Inquiry 22:396-403.
51. Ross-Degnan, D., and S.B. Soumerai. 1996. HMO Formularies and Care Costs. Lancet 347:1264.
52. Rucker, T.D. 1999. A Public-Policy Strategy for Drug Formularies: Preparation or Procrastination? American Journal Health System Pharmacy 56:2338-42.
53. Rucker, T.D., and G. Schiff. 1990. Drug Formularies: Myths-in-Formation. Medical Care 28:928-42.
54. Shadish, W., T. Cook, and D. Campbell. 2002. Experimental and Quasi-Experimental Designs for Generalized Causal Inference. Boston: Houghton Mifflin.
55. Sica, J.M. 2001. Managing Prescription Drug Costs. Employee Benefits Journal 26:35-40.
56. Smalley, W.E., M.R. Griffin, R.L. Fought, L. Sullivan, and W.A. Ray. 1995. Effect of a Prior-Authorization Requirement on the Use of Nonsteroidal Antiinflammatory Drugs by Medicaid Patients. New England Journal of Medicine 332:1612-7.
57. Soumerai, S.B., J. Avorn, D. Ross-Degnan, and S. Gortmaker. 1987. Payment Restrictions for Prescription Drugs under Medicaid. Effects on Therapy, Cost, and Equity. New England Journal of Medicine 317:550-6.
58. Soumerai, S.B., and D. Ross-Degnan. 1999- Inadequate Prescription-Drug Coverage for Medicare Enrollees - A Call to Action. New England Journal of Medicine 340:722-8.
59. Soumerai, S.B., D. Ross-Degnan, J. Avorn, T McLaughlin, and I. Choodnovskiy. 1991. Effects of Medicaid Drug-Payment Limits on Admission to Hospitals and Nursing Homes. New England Journal of Medicine 325:1072-7.
60. Soumerai, S.B., D. Ross-Degnan, E.E. Fortess, and J. Abelson. 1993. A Critical Analysis of Studies of State Drug Reimbursement Policies: Research in Need of Discipline. Milbank Quarterly 71:217-52.
61. Stuart, B., and J. Grana. 1998. Ability to Pay and the Decision to Medicate. Medical Care 36:202-11.
62. Stuart, B., and C. Zacker. 1999. Who Bears the Burden of Medicaid Drug Copayment Policies? Health Affairs 18:201-12.
63. Takeda Prescription Drug Benefit Cost and Plan Design Survey Report. 2002. Albuquerque, N.M.: Wellman Publishing.
64. Tamblyn, R., R. Laprise, J.A Hanley, M. Abrahamowicz, S. Scott, N. Mayo, J. Hurley, R. Grad, E. Latimer, R. Perreault, P. McLeod, A. Huang, P. Larochelle, and L. Mallet. 2001. Adverse Events Associated with Prescription Drug Cost-Sharing among Poor and Elderly Persons. Journal of the American Medical Association 285:421-9.
65. Taylor, A.J., K. Grace, J. Swiecki, R. Hyatt, H. Gibbs, M. Sheikh, P.G. O'Malley, S.P. Lowenthal, M. West, J. Spain, K. Maneval, and D.L. Jones. 2001. Lipid-Lowering Efficacy, Safety, and Costs of a Large-Scale Therapeutic Statin Formulary Conversion Program. Pharmacotherapy 21:1130-9.
66. Thomas, C.P., S.S. Wallack, S. Lee, and G.A. Ritter. 2002. Impact of Health Plan Design and Management on Retirees' Prescription Drug Use and Spending, 2001. Health Affairs Supplementary Web Exclusives W408-19.
67. Tseng, C.W., R.H. Brook, E. Keeler, and C.M. Mangione. 2003. Impact of an Annual Dollar Limit or "Cap" on Prescription Drug Benefits for Medicare Patients. Journal of the American Medical Association 290:222-7.
68. U.S. Pharmacopeia. 2004. Background: Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Available at http://www.usp.org/pdf/ drugInformation/mmg/mmaOverview.pdf (accessed August 19, 2004).
69. Witt, D.M., D.J. Tillman, C.M. Evans, T.V. Plotkin, and M.A. Sadler. 2003- Evaluation of the Clinical and Economic Impact of a Brand Name-to-Generic Warfarin Sodium Conversion Program. Pharmacotherapy 23:360-8.
70. Xu, K.T. 2003. Financial Disparities in Prescription Drug Use between Elderly and Nonelderly Americans. Health Affairs 22:210-21.